New Drug Rules On Licensing, Trials, Surveillance Edge Closer In Singapore
This article was originally published in SRA
Executive Summary
Pharmaceutical companies doing business in Singapore are being advised to review the procedures they have in place relating to drug licensing, conducting clinical trials and responding to post-market surveillance in light of proposed legislative changes in the country.